Lumigan (bimatoprost)
- Region
- 🇪🇺 EU
- Active substance
- bimatoprost
- Company
- AbbVie Deutschland GmbH & Co. KG
- Status
- Authorised
- Therapeutic area
- Glaucoma, Open-Angle; Ocular Hypertension
- EU approval
- Fri 08 Mar 2002
- Application
- EMEA/H/C/000391
- ATC
- S01EE03
- Official record
- www.ema.europa.eu
Indication
Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Durysta Application withdrawn · AbbVie Deutschland GmbH & Co. KG
- 🇪🇺 Ganfort Authorised · AbbVie Deutschland GmbH & Co. KG
Follow Lumigan
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.